Publication Name	World Journal of Gastroenterology
Manuscript ID	20414
Country	China

Received	2015-06-04 09:30
Peer-Review Started	2015-06-06 17:18
To Make the First Decision	2015-07-13 15:22
Return for Revision	2015-07-17 16:55
Revised	2015-07-28 23:43
Second Decision	2015-09-12 22:04
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2015-09-14 11:35
Articles in Press	2015-09-14 11:35
Publication Fee Transferred
Edit the Manuscript by Language Editor	2015-09-26 08:06
Typeset the Manuscript	2015-10-21 14:03
Publish the Manuscript Online	2015-11-11 13:34

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Topic Highlights
Article Title	Sorafenib-based combined molecule targeting in treatment of hepatocellular carcinoma
Manuscript Source	Invited Manuscript
All Author List	Jian-Jun Gao, Zhen-Yan Shi, Ju-Feng Xia, Yoshinori Inagaki and Wei Tang
Funding Agency and Grant Number
Corresponding Author	Jian-Jun Gao, PhD, Department of Pharmacology, School of Pharmaceutical Sciences, Qingdao University, 38 Dengzhou Road, Qingdao 266021, Shandong Province, China. gaojj@qdu.edu.cn
Key Words	Angiogenesis; Mammalian target of rapamycin; Extracellular-signal regulated kinase; Endothelial growth factor receptor; Histone deacetylases
Core Tip	Cancer is regarded as a heterogeneous disease, with no exception of hepatocellular carcinoma (HCC), which requires combined chemotherapy. HCC is not sensitive to most currently used conventional cytotoxic drugs. The approval of sorafenib, a molecular targeted drug that inhibits RAF kinase and several other angiogenesis-related receptor tyrosine kinases, opens a door for systematic treatment of HCC. The pathogenesis of HCC involves hyperactivation of several signal pathways and aberrant expression of some key molecules, suggesting combination treatment may yield major improvements in the management of this disease. The emerging sorafenib-based combination treatments are reviewed in the present article.
Publish Date	2015-11-11 13:34
Citation	Gao JJ, Shi ZY, Xia JF, Inagaki Y, Tang W. Sorafenib-based combined molecule targeting in treatment of hepatocellular carcinoma. World J Gastroenterol 2015; 21(42): 12059-12070
URL	http://www.wjgnet.com/1007-9327/full/v21/i42/12059.htm
DOI	http://dx.doi.org/10.3748/wjg.v21.i42.12059

Full Article (PDF)	WJG-21-12059.pdf
Full Article (Word)	WJG-21-12059.doc
Manuscript File	20414-Review.docx
Answering Reviewers	20414-Answering reviewers.pdf
Audio Core Tip	20414-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	20414-Conflict-of-interest statement.pdf
Copyright License Agreement	20414-Copyright assignment.pdf
Peer-review Report	20414-Peer-review(s).pdf
Scientific Misconduct Check	20414-Scientific misconduct check.pdf
Scientific Editor Work List	20414-Scientific editor work list.pdf